Cepheid - Medical Equipment - Deals and Alliances Profile

Date: April 24, 2018
Pages: 26
Price:
US$ 250.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C6BB6EA5AA0EN
Leaflet:

Download PDF Leaflet

Cepheid - Medical Equipment - Deals and Alliances Profile
Summary

Cepheid, a subsidiary of Danaher Corporation, is a molecular diagnostic company that develops, manufactures and markets molecular systems and tests for clinical and non-clinical markets. The company offers in vitro diagnostic tests for health care associated infections, critical infectious diseases, sexual health, and oncology and genetics; molecular diagnostic systems; and reagents and parts. Cepheid distributes its products directly and also through a network of distributors across Americas, Asia, Europe, Africa and the Middle East regions. The company has partnership with small and large biopharmaceutical companies to develop therapies in anti-infective, critical infectious disease and oncology areas. Cepheid is headquartered in Sunnyvale, California, the US.

Cepheid - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope
  • Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
  • Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
  • Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
  • Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
  • Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
  • Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
  • Business Description - A brief description of the company's operations.
  • Key Employees - A list of the key executives of the company.
  • Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
  • Key Competitors - A list of the key competitors of the company.
  • Key Recent Developments - A brief on recent news about the company.
Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
  • The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
  • The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
  • Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
  • The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
  • Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
  • Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company.

NOTE: Out of security concerns GlobalData requires using corporate email address.
Cepheid, Medical Equipment, Deals By Year, 2012 to YTD 2018
Cepheid, Medical Equipment Deals By Type, 2012 to YTD 2018
Cepheid, Medical Equipment, Deals By Region, 2012 to YTD 2018
Cepheid, Medical Equipment, Deals By Market, 2012 to YTD 2018
Cepheid, Medical Equipment, Deals Summary, 2012 to YTD 2018
Cepheid, Medical Equipment, Deal Details
Partnerships
Cell Signaling Technology Enters Into Licensing Agreement With Cepheid For Personalized Cancer Diagnostics
SpeeDx Enters into Distribution Agreement with Cepheid
Novacyt Enters into Partnership with Cepheid
Cepheid Enters into Agreement with Foundation for Innovative New Diagnostics
Foundation for Innovative New Diagnostics Enters into Agreement with Cepheid and Rutgers
Cepheid Enters into Co-Development Agreement with AstraZeneca, Cubist Pharma and GSK
Cepheid Enters Into Co-Development Agreement With Oregon Health and Science University
Debt Offering
Cepheid Completes Private Placement Of Notes Due 2021 For US$345 Million
Acquisition
Danaher Acquires Cepheid
Cepheid - Key Competitors
Cepheid - Key Employees
Cepheid - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Government and Public Interest
Feb 20, 2018: New IDSA/SHEA Guidelines Highlight Critical Role of PCR Testing in C. difficile Diagnosis
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Cepheid, Medical Equipment, Key Facts, 2015
Cepheid, Medical Equipment, Deals Summary, 2012 to YTD 2018
Cepheid, Medical Equipment, Deals By Year, 2012 to YTD 2018
Cepheid, Medical Equipment Deals By Type, 2012 to YTD 2018
Cepheid, Medical Equipment, Deals By Region, 2012 to YTD 2018
Cepheid, Deals By Market, 2012 to YTD 2018
Cepheid, Medical Equipment, Deals Summary, 2012 to YTD 2018
Cell Signaling Technology Enters Into Licensing Agreement With Cepheid For Personalized Cancer Diagnostics
SpeeDx Enters into Distribution Agreement with Cepheid
Novacyt Enters into Partnership with Cepheid
Cepheid Enters into Agreement with Foundation for Innovative New Diagnostics
Foundation for Innovative New Diagnostics Enters into Agreement with Cepheid and Rutgers
Cepheid Enters into Co-Development Agreement with AstraZeneca, Cubist Pharma and GSK
Cepheid Enters Into Co-Development Agreement With Oregon Health and Science University
Cepheid Completes Private Placement Of Notes Due 2021 For US$345 Million
Danaher Acquires Cepheid
Cepheid, Key Competitors
Cepheid, Key Employees
Cepheid, Subsidiaries

LIST OF FIGURES

Cepheid, Medical Equipment, Deals by Type, 2012 to YTD 2018
Cepheid, Medical Equipment, Deals By Year, 2012 to YTD 2018
Cepheid, Medical Equipment, Deals By Region, 2012 to YTD 2018
Cepheid, Medical Equipment, Deals By Market, 2012 to YTD 2018
Cepheid, Medical Equipment, Deals By Year, 2012 to YTD 2018
Cepheid, Medical Equipment, Deals by Type, 2012 to YTD 2018
Cepheid, Medical Equipment, Deals By Region, 2012 to YTD 2018
Cepheid, Medical Equipment, Deals by Market, 2012 to YTD 2018
Skip to top


Ask Your Question

Cepheid - Medical Equipment - Deals and Alliances Profile
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: